{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T13:25:46Z","timestamp":1795008346391,"version":"4.9.1"},"reference-count":51,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100024017","name":"Sheba Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024017","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.amjmed.2026.03.029","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T16:28:57Z","timestamp":1774283337000},"page":"1043-1051","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antiphospholipid antibodies among hospitalized patients predict mortality and readmission: A real-world 10-years cohort study"],"prefix":"10.1016","volume":"139","author":[{"given":"Soad","family":"Haj Yahia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadas","family":"Lazarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanely","family":"Niznik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronen","family":"Shavit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aharon","family":"Lubetsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Agmon-Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.amjmed.2026.03.029_bib0001","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1182\/blood-2017-11-814681","article-title":"Antiphospholipid antibodies induce thrombosis by PP2A activation via apoER2-Dab2-SHC1 complex formation in endothelium","volume":"131","author":"Sacharidou","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.amjmed.2026.03.029_bib0002","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13317-020-00131-3","article-title":"Profiles of criteria and non-criteria anti-phospholipid autoantibodies are associated with clinical phenotypes of the antiphospholipid syndrome","volume":"11","author":"Volkov","year":"2020","journal-title":"Auto Immun Highlights"},{"issue":"8","key":"10.1016\/j.amjmed.2026.03.029_bib0003","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.autrev.2014.02.003","article-title":"14th International congress on antiphospholipid antibodies task force report on obstetric antiphospholipid syndrome","volume":"13","author":"de Jesus","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.amjmed.2026.03.029_bib0004","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s10067-014-2486-5","article-title":"The spectrum between antiphospholipid syndrome and systemic lupus erythematosus","volume":"33","author":"Agmon-Levin","year":"2014","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.amjmed.2026.03.029_bib0005","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"10","key":"10.1016\/j.amjmed.2026.03.029_bib0006","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/art.42624","article-title":"The 2023 ACR\/EULAR Antiphospholipid Syndrome classification criteria","volume":"75","author":"Barbhaiya","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"13","key":"10.1016\/j.amjmed.2026.03.029_bib0007","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1177\/0961203313504633","article-title":"Ferritin in the antiphospholipid syndrome and its catastrophic variant (cAPS)","volume":"22","author":"Agmon-Levin","year":"2013","journal-title":"Lupus"},{"issue":"3","key":"10.1016\/j.amjmed.2026.03.029_bib0008","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/annrheumdis-2016-209770","article-title":"EULAR recommendations for women\u2019s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and\/or antiphospholipid syndrome","volume":"76","author":"Andreoli","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.amjmed.2026.03.029_bib0009","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients","volume":"74","author":"Cervera","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.amjmed.2026.03.029_bib0010","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3390\/life13040891","article-title":"Heart valve surgery in Antiphospholipid syndrome patients-morbidity and mortality","volume":"13","author":"Eviatar","year":"2023","journal-title":"Life"},{"issue":"3","key":"10.1016\/j.amjmed.2026.03.029_bib0011","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4103\/0366-6999.198934","article-title":"Antiphospholipid antibody titers and clinical outcomes in patients with recurrent miscarriage and Antiphospholipid antibody syndrome: a prospective study","volume":"130","author":"Song","year":"2017","journal-title":"Chin Med J"},{"issue":"2","key":"10.1016\/j.amjmed.2026.03.029_bib0012","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.healun.2021.10.016","article-title":"Chronic thromboembolic pulmonary hypertension in patients with antiphospholipid syndrome: risk factors and management","volume":"41","author":"Rosen","year":"2022","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.amjmed.2026.03.029_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.824775","article-title":"Long term follow up of patients with primary obstetric antiphospholipid syndrome","volume":"13","author":"Niznik","year":"2022","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.amjmed.2026.03.029_bib0014","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/bjc.1995.353","article-title":"Increased thromboembolic incidence in anti-cardiolipin-positive patients with malignancy","volume":"72","author":"Zuckerman","year":"1995","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.amjmed.2026.03.029_bib0015","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1006\/jaut.2000.0409","article-title":"Epidemiology of the antiphospholipid antibody syndrome","volume":"15","author":"Petri","year":"2000","journal-title":"J Autoimmun"},{"issue":"3","key":"10.1016\/j.amjmed.2026.03.029_bib0016","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1445-5994.1990.tb01025.x","article-title":"Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population","volume":"20","author":"Shi","year":"1990","journal-title":"Aust N Z J Med"},{"issue":"17","key":"10.1016\/j.amjmed.2026.03.029_bib0017","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1182\/blood-2011-03-340232","article-title":"Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study","volume":"118","author":"Pengo","year":"2011","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.amjmed.2026.03.029_bib0018","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1177\/0961203314545410","article-title":"Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study","volume":"23","author":"Mustonen","year":"2014","journal-title":"Lupus"},{"issue":"9","key":"10.1016\/j.amjmed.2026.03.029_bib0019","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1111\/j.1538-7836.2005.01485.x","article-title":"Lupus anticoagulants and the risk of a first episode of deep venous thrombosis","volume":"3","author":"de Groot","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"22","key":"10.1016\/j.amjmed.2026.03.029_bib0020","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1182\/blood-2014-11-611129","article-title":"Increased mortality in patients with the lupus anticoagulant: the vienna lupus anticoagulant and thrombosis study (LATS)","volume":"125","author":"Gebhart","year":"2015","journal-title":"Blood."},{"issue":"5","key":"10.1016\/j.amjmed.2026.03.029_bib0021","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2002-02-0441","article-title":"Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature","volume":"101","author":"Galli","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.amjmed.2026.03.029_bib0022","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ijcard.2019.10.042","article-title":"Anti-phospholipid antibody prevalence and association with subclinical atherosclerosis and atherothrombosis in the general population","volume":"300","author":"Selmi","year":"2020","journal-title":"Int J Cardiol"},{"issue":"11","key":"10.1016\/j.amjmed.2026.03.029_bib0023","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S1474-4422(09)70239-X","article-title":"Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study","volume":"8","author":"Urbanus","year":"2009","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.amjmed.2026.03.029_bib0024","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1080\/01616412.1999.11740992","article-title":"Anticardiolipin antibodies are an independent risk factor for ischemic stroke","volume":"21","author":"Zieli\u00f1ska","year":"1999","journal-title":"Neurol Res"},{"issue":"4","key":"10.1016\/j.amjmed.2026.03.029_bib0025","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0002-9343(98)00060-6","article-title":"Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group","volume":"104","author":"Schulman","year":"1998","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2026.03.029_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2021.100134","article-title":"Role of antiphospholipid antibodies in the diagnosis of antiphospholipid syndrome","volume":"4","author":"Devreese","year":"2021","journal-title":"J Transl Autoimmun"},{"key":"10.1016\/j.amjmed.2026.03.029_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109845","article-title":"Antiphospholipid antibodies are enriched post-acute COVID-19 but do not modulate the thrombotic risk","volume":"257","author":"Emmenegger","year":"2023","journal-title":"Clin Immunol"},{"issue":"5","key":"10.1016\/j.amjmed.2026.03.029_bib0028","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.semarthrit.2006.11.003","article-title":"Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome","volume":"36","author":"Zandman-Goddard","year":"2007","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.amjmed.2026.03.029_bib0029","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1191\/096120399678847524","article-title":"Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes","volume":"8","author":"Chapman","year":"1999","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.amjmed.2026.03.029_bib0030","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s40744-020-00273-w","article-title":"Antiphospholipid antibodies in inflammatory and autoimmune rheumatic and musculoskeletal diseases beyond lupus: a systematic review of the available evidence","volume":"8","author":"El Hasbani","year":"2021","journal-title":"Rheumatol Ther"},{"issue":"2","key":"10.1016\/j.amjmed.2026.03.029_bib0031","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1600-0897.2009.00717.x","article-title":"Antiphospholipid antibodies induce a pro-inflammatory response in first trimester trophoblast via the TLR4\/MyD88 pathway","volume":"62","author":"Mulla","year":"2009","journal-title":"Am J Reprod Immunol"},{"key":"10.1016\/j.amjmed.2026.03.029_bib0032","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3389\/fimmu.2019.00449","article-title":"Complement in the pathophysiology of the antiphospholipid syndrome","volume":"10","author":"Chaturvedi","year":"2019","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.amjmed.2026.03.029_bib0033","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jri.2007.02.007","article-title":"Antiphospholipid antibodies and pregnancy loss: a disorder of inflammation","volume":"77","author":"Salmon","year":"2008","journal-title":"J Reprod Immunol"},{"issue":"5","key":"10.1016\/j.amjmed.2026.03.029_bib0034","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1177\/1120672120968729","article-title":"Antiphospholipid antibodies may be associated with uveitis","volume":"31","author":"Shapira","year":"2021","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"10.1016\/j.amjmed.2026.03.029_bib0035","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/OGX.0b013e3181c97809","article-title":"Is obstetric antiphospholipid syndrome a primary nonthrombotic, proinflammatory, complement-mediated disorder related to antiphospholipid antibodies?","volume":"65","author":"Alijotas-Reig","year":"2010","journal-title":"Obstet Gynecol Surv"},{"issue":"5","key":"10.1016\/j.amjmed.2026.03.029_bib0036","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1177\/0961203308090025","article-title":"Pathogenic role of antiphospholipid antibodies","volume":"17","author":"Salmon","year":"2008","journal-title":"Lupus"},{"key":"10.1016\/j.amjmed.2026.03.029_bib0050","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.764702","article-title":"Differences in endothelial activation and dysfunction induced by antiphospholipid antibodies among groups of patients with thrombotic, refractory, and non-refractory antiphospholipid syndrome","volume":"12","author":"Vel\u00e1squez","year":"2021","journal-title":"Front Physiol"},{"issue":"7","key":"10.1016\/j.amjmed.2026.03.029_bib0051","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1177\/0961203312438631","article-title":"Pathophysiology of thrombotic APS: where do we stand?","volume":"21","author":"de Groot","year":"2012","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.amjmed.2026.03.029_bib0052","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/BOR.0000000000000926","article-title":"An update on inflammation in antiphospholipid syndrome","volume":"35","author":"Ambati","year":"2023","journal-title":"Curr Opin Rheumatol"},{"issue":"18","key":"10.1016\/j.amjmed.2026.03.029_bib0053","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.93897","article-title":"Activated signature of antiphospholipid syndrome neutrophils reveals potential therapeutic target","volume":"2","author":"Knight","year":"2017","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.amjmed.2026.03.029_bib0037","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000048623","article-title":"Anticardiolipin antibodies and mortality in patients with ischemic stroke: a prospective follow-up study","volume":"21","author":"Tanne","year":"2002","journal-title":"Neuroepidemiology"},{"issue":"9","key":"10.1016\/j.amjmed.2026.03.029_bib0038","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1161\/01.STR.28.9.1660","article-title":"IgG anticardiolipin antibody titer >40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study","volume":"28","author":"Levine","year":"1997","journal-title":"Stroke"},{"issue":"5","key":"10.1016\/j.amjmed.2026.03.029_bib0039","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/rheumatology\/kev423","article-title":"Association between antiphospholipid antibodies and all-cause mortality among end-stage renal disease patients with and without SLE: a retrospective cohort study","volume":"55","author":"Broder","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"289","key":"10.1016\/j.amjmed.2026.03.029_bib0040","first-page":"397","article-title":"Antibodies to cardiolipin in stroke: association with mortality and functional recovery in patients without systemic lupus erythematosus","volume":"79","author":"Chakravarty","year":"1991","journal-title":"Q J Med"},{"issue":"8","key":"10.1016\/j.amjmed.2026.03.029_bib0041","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0002-9343(00)00600-8","article-title":"Association between anticardiolipin antibodies and mortality in patients with peripheral arterial disease","volume":"109","author":"Puisieux","year":"2000","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.amjmed.2026.03.029_bib0042","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1160\/TH14-05-0416","article-title":"Diagnosis and management of non-criteria obstetric antiphospholipid syndrome","volume":"113","author":"Arachchillage","year":"2015","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1016\/j.amjmed.2026.03.029_bib0043","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/rheumatology\/keaa203","article-title":"EUREKA algorithm predicts obstetric risk and response to treatment in women with different subsets of anti-phospholipid antibodies","volume":"60","author":"Pregnolato","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.amjmed.2026.03.029_bib0044","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1111\/jth.12014","article-title":"Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: evaluation of 23 possible combinations of antiphospholipid antibody specificities","volume":"10","author":"Sciascia","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"8","key":"10.1016\/j.amjmed.2026.03.029_bib0047","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/rheumatology\/kes388","article-title":"GAPSS: the global anti-phospholipid syndrome score","volume":"52","author":"Sciascia","year":"2013","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.amjmed.2026.03.029_bib0048","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s13023-021-01906-1","article-title":"Reducing the diagnostic delay in antiphospholipid syndrome over time: a real world observation","volume":"16","author":"Radin","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"10.1016\/j.amjmed.2026.03.029_bib0049","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11926-021-01038-2","article-title":"Epidemiology of antiphospholipid syndrome in the general population","volume":"23","author":"Dabit","year":"2022","journal-title":"Curr Rheumatol Rep"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934326002299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934326002299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T20:24:13Z","timestamp":1781727853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934326002299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0002934326002299"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2026.03.029","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiphospholipid antibodies among hospitalized patients predict mortality and readmission: A real-world 10-years cohort study","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2026.03.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}